FDA clarifies Movantik label

FDA updated the label for Movantik naloxegol to clarify that the compound is approved to treat opioid-induced constipation

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE